Загрузка видео...

Не удалось загрузить видео

На главную

The NCCN® Clinical Practice Guidelines now include ANKTIVA® plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This update reflects continued progress in expanding treatment considerations for patients facing limited options following BCG therapy. Learn more:

ImmunityBio's profile picture

ImmunityBio, Inc.

20,081 subscribers

23,520 просмотров • 6 месяцев назад •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:
0:14

Today, the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA® for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more:

ImmunityBio, Inc.

14,278 просмотров • 8 месяцев назад

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:
0:14

ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA® + CAR-NK-based regimen. As recent American Cancer Society data shows that brain cancer is now the third leading cause of cancer-related death among adults ages 20–49, these findings underscore the urgency of continued innovation in this disease. Read more:

ImmunityBio, Inc.

107,673 просмотров • 8 месяцев назад

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function. This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development. Learn more:
0:13

GB-0895, our anti-TSLP monoclonal antibody, has entered a Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD)—its second indication following asthma. Designed using generative optimization, GB-0895 was built for high potency, extended half-life, and targeted function. This is the fourth clinical trial for a molecule designed on our platform and reflects how generative optimization can produce antibodies with defined therapeutic properties that advance efficiently into clinical development. Learn more:

Generate:Biomedicines

10,481 просмотров • 1 год назад

Dear Ministry of Ayush as suggested by you in your post, I would like to report brutalistic and torture treatment by your own registered medical practitioner, and Ayurveda Gold Medalist, Mr. Jaldipsinh P. Jhala who has been promoting and promising false claims regarding Ayurvedic treatments for various chronic diseases including aseptic surgical procedures done on patients and publicly putting up videos to promote his nonsensical treatment which your Universities have taught him and given gold medal for. He burns patients with dental infections, pokes holes in the mouth of elderly patients when severe ulcerative disease, bleeds patients with necrosis of the hip. And so much more. Please see some attached videos and kindly take action. He also claims to improve infants memory, immunity and digestion by feeding them gold and honey and sells gold-honey kits for huge profits on this website and Instagram account. Please report and take action on this account for ridiculously endangering patients with false promises, using brutal ancient treatments. First, keep your house in order. His account:
0:38

Dear Ministry of Ayush as suggested by you in your post, I would like to report brutalistic and torture treatment by your own registered medical practitioner, and Ayurveda Gold Medalist, Mr. Jaldipsinh P. Jhala who has been promoting and promising false claims regarding Ayurvedic treatments for various chronic diseases including aseptic surgical procedures done on patients and publicly putting up videos to promote his nonsensical treatment which your Universities have taught him and given gold medal for. He burns patients with dental infections, pokes holes in the mouth of elderly patients when severe ulcerative disease, bleeds patients with necrosis of the hip. And so much more. Please see some attached videos and kindly take action. He also claims to improve infants memory, immunity and digestion by feeding them gold and honey and sells gold-honey kits for huge profits on this website and Instagram account. Please report and take action on this account for ridiculously endangering patients with false promises, using brutal ancient treatments. First, keep your house in order. His account:

TheLiverDoc™

103,314 просмотров • 2 месяцев назад

The Board of REACT19 regrets to inform our community of the sudden cancellation of this week’s meeting of the Advisory Committee on Immunization Practices (ACIP) at the CDC. The meeting was cancelled following a federal court ruling that blocked recent vaccine policy changes and invalidated the current ACIP advisory panel while legal challenges move forward. For many in our community, this meeting represented a long-awaited opportunity. After more than five years of waiting, patients and families had prepared impact statements in hopes that the urgent need for clinical recognition, research, and care for those suffering from serious post-vaccination conditions would finally be discussed. For those living with these conditions, this cancellation is deeply painful. It means more waiting, more uncertainty, and more time without the clinical guidance needed to help physicians recognize, diagnose, and treat patients who have been suffering for years. Our hearts are with every member of this community who had hoped their voice would finally be heard this week. However, even in this difficult moment, important progress continues. On March 18, REACT19 will still be part of a historic step forward at the CDC. A proposal for a new ICD-10 diagnostic code related to post-COVID-19 vaccination conditions will be presented, opening a public comment period and moving the medical system closer to formally recognizing these patients. Diagnostic codes are more than administrative tools. They are a critical foundation for clinical recognition, medical education, research, insurance coverage, and ultimately the development of treatments. Establishing an ICD-10 code would represent an important step toward building the clinical infrastructure needed to care for patients who have too often been left without answers. While the cancellation of the ACIP meeting is a heartbreaking setback for our community, the work to achieve medical recognition and appropriate care continues. If the U.S. Department of Health and Human Services prevails in its appeal, the ACIP process may resume. In the meantime, REACT19 remains committed to ensuring that the voices of patients are heard and that progress toward recognition, research, and care does not stop. To every patient and family who has shared their story and stood with us through years of uncertainty: we see you, we hear you, and we will continue advocating for the care and recognition you deserve. — Board of Directors REACT19
0:20

The Board of REACT19 regrets to inform our community of the sudden cancellation of this week’s meeting of the Advisory Committee on Immunization Practices (ACIP) at the CDC. The meeting was cancelled following a federal court ruling that blocked recent vaccine policy changes and invalidated the current ACIP advisory panel while legal challenges move forward. For many in our community, this meeting represented a long-awaited opportunity. After more than five years of waiting, patients and families had prepared impact statements in hopes that the urgent need for clinical recognition, research, and care for those suffering from serious post-vaccination conditions would finally be discussed. For those living with these conditions, this cancellation is deeply painful. It means more waiting, more uncertainty, and more time without the clinical guidance needed to help physicians recognize, diagnose, and treat patients who have been suffering for years. Our hearts are with every member of this community who had hoped their voice would finally be heard this week. However, even in this difficult moment, important progress continues. On March 18, REACT19 will still be part of a historic step forward at the CDC. A proposal for a new ICD-10 diagnostic code related to post-COVID-19 vaccination conditions will be presented, opening a public comment period and moving the medical system closer to formally recognizing these patients. Diagnostic codes are more than administrative tools. They are a critical foundation for clinical recognition, medical education, research, insurance coverage, and ultimately the development of treatments. Establishing an ICD-10 code would represent an important step toward building the clinical infrastructure needed to care for patients who have too often been left without answers. While the cancellation of the ACIP meeting is a heartbreaking setback for our community, the work to achieve medical recognition and appropriate care continues. If the U.S. Department of Health and Human Services prevails in its appeal, the ACIP process may resume. In the meantime, REACT19 remains committed to ensuring that the voices of patients are heard and that progress toward recognition, research, and care does not stop. To every patient and family who has shared their story and stood with us through years of uncertainty: we see you, we hear you, and we will continue advocating for the care and recognition you deserve. — Board of Directors REACT19

React19 - Official

33,505 просмотров • 6 месяцев назад

BUIDL is now on Solana! Following the one-year anniversary of BUIDL’s launch, BlackRock and Securitize are expanding access with a new share class on the Solana network. This milestone marks an important step in the continued institutional adoption of tokenized real-world assets. 🌍 Why Solana? Solana’s high throughput, low costs, and scalability make it an ideal blockchain to support institutional-grade RWAs. By expanding to Solana, BUIDL is now more accessible to a broader range of investors and applications. Find out what this means for the future of tokenized finance 👇
0:10

BUIDL is now on Solana! Following the one-year anniversary of BUIDL’s launch, BlackRock and Securitize are expanding access with a new share class on the Solana network. This milestone marks an important step in the continued institutional adoption of tokenized real-world assets. 🌍 Why Solana? Solana’s high throughput, low costs, and scalability make it an ideal blockchain to support institutional-grade RWAs. By expanding to Solana, BUIDL is now more accessible to a broader range of investors and applications. Find out what this means for the future of tokenized finance 👇

Securitize

252,518 просмотров • 1 год назад

How can a 99% accurate medical test give you a 9% chance of having the disease if it comes back positive? 🤔 If you are in medicine this is the SINGLE most important diagnostic testing concept to know. Welcome to the difference between specificity and positive predictive value. Sensitivity & specificity are fixed test properties. These do not factor how common a disease is (prevalence) Positive Predictive Value (probability a positive test reflects having a disease) factors in prevalence and is actually more important to clinicians than sens/spec. It is harder to figure out though because we need to have a gestault for how prevalent a disease is for the EXACT patient we are seeing. If you have very low prevalence, even with a great test, most positives are false positives. This is why screening low-risk patients can result in many false positives and harm To master this, just play with the calculator yourself and you will see!!!!👇
0:12

How can a 99% accurate medical test give you a 9% chance of having the disease if it comes back positive? 🤔 If you are in medicine this is the SINGLE most important diagnostic testing concept to know. Welcome to the difference between specificity and positive predictive value. Sensitivity & specificity are fixed test properties. These do not factor how common a disease is (prevalence) Positive Predictive Value (probability a positive test reflects having a disease) factors in prevalence and is actually more important to clinicians than sens/spec. It is harder to figure out though because we need to have a gestault for how prevalent a disease is for the EXACT patient we are seeing. If you have very low prevalence, even with a great test, most positives are false positives. This is why screening low-risk patients can result in many false positives and harm To master this, just play with the calculator yourself and you will see!!!!👇

Ross Prager

16,038 просмотров • 7 месяцев назад

Last week I did spot checks at Masaka Regional Referral Hospital after hearing from the public and whistleblowers. Yesterday I met with the hospital administration and we agreed on the following; 1. Accountability & Monitoring: Deploy more hospital inspectors and staff to the control room to monitor CCTV cameras. Take firm action against absenteeism, extortion of money from patients, and unprofessional conduct by some health workers. 2. No Excuses: The administration informed me that there has been a recent salary enhancement and more recruitment. Therefore, there is no justification for absenteeism without valid reason, extortion, or unprofessionalism. 3. Oversight: I committed to visiting the hospital once every month to monitor progress together with the administration. Spot checks will also continue based on reports from whistleblowers. 4. Service Delivery: We discussed the delayed payment of interns and the need for Government to make scan services completely free, since most people cannot afford them. I also raised complaints from Banna Masaka that some medical workers, especially nurses, are rude to patients. The administration promised to continue counseling staff to be more compassionate and patient-centered. 5. Progress: With the new complex now operational, no mothers are sleeping on the floor anymore and our NICU is fully equipped. 6. Fighting Fraud: I ordered the arrest of a conman who has been defrauding patients. The administration claims some people keep him in the hospital, saying he is an "NRM cadre". It is unacceptable to use NRM or any political party as a cover to steal from patients. I also committed to lobbying Government for more infrastructure and drugs for the hospital. Public money must be used for public service delivery — for every mother, father, youth, and child. #kisanjanomoresleep #kisanjanomorecorruption #MasakaCity #HealthForAll #ZeroToleranceToCorruption
0:17

Last week I did spot checks at Masaka Regional Referral Hospital after hearing from the public and whistleblowers. Yesterday I met with the hospital administration and we agreed on the following; 1. Accountability & Monitoring: Deploy more hospital inspectors and staff to the control room to monitor CCTV cameras. Take firm action against absenteeism, extortion of money from patients, and unprofessional conduct by some health workers. 2. No Excuses: The administration informed me that there has been a recent salary enhancement and more recruitment. Therefore, there is no justification for absenteeism without valid reason, extortion, or unprofessionalism. 3. Oversight: I committed to visiting the hospital once every month to monitor progress together with the administration. Spot checks will also continue based on reports from whistleblowers. 4. Service Delivery: We discussed the delayed payment of interns and the need for Government to make scan services completely free, since most people cannot afford them. I also raised complaints from Banna Masaka that some medical workers, especially nurses, are rude to patients. The administration promised to continue counseling staff to be more compassionate and patient-centered. 5. Progress: With the new complex now operational, no mothers are sleeping on the floor anymore and our NICU is fully equipped. 6. Fighting Fraud: I ordered the arrest of a conman who has been defrauding patients. The administration claims some people keep him in the hospital, saying he is an "NRM cadre". It is unacceptable to use NRM or any political party as a cover to steal from patients. I also committed to lobbying Government for more infrastructure and drugs for the hospital. Public money must be used for public service delivery — for every mother, father, youth, and child. #kisanjanomoresleep #kisanjanomorecorruption #MasakaCity #HealthForAll #ZeroToleranceToCorruption

Justine Nameere Nsubuga

34,995 просмотров • 1 месяц назад

Meet the next-generation approach to cancer treatment. 💊🌟 Switchable CAR-T (sCAR-T) is a programmable immunotherapy designed to give scientists and clinicians greater control over how—and when—the immune system attacks cancer. This modular CAR-T platform activates engineered immune cells only in the presence of an antibody “switch.” Without the switch, the cells remain inactive, an approach designed to improve precision and lifespan, while potentially reducing the risk of uncontrolled immune responses. Scientists at Scripps Research’s drug development division, Calibr-Skaggs Institute for Innovative Medicines, have completed a Phase 1 clinical trial evaluating the safety of the sCAR-T platform (CLBR001) paired with a CD19-targeted switch (SWI019) for B-cell malignancies (NCT04450069). Initial results announced underscore the potential of this therapy. The technology is now being tested in a Phase 1 clinical trial for metastatic breast cancer, with an additional Phase 1 trial for autoimmune diseases launching this year. #WorldCancerDay #CancerResearch #Immunotherapy #BreastCancerResearch #ClinicalTrials
0:14

Meet the next-generation approach to cancer treatment. 💊🌟 Switchable CAR-T (sCAR-T) is a programmable immunotherapy designed to give scientists and clinicians greater control over how—and when—the immune system attacks cancer. This modular CAR-T platform activates engineered immune cells only in the presence of an antibody “switch.” Without the switch, the cells remain inactive, an approach designed to improve precision and lifespan, while potentially reducing the risk of uncontrolled immune responses. Scientists at Scripps Research’s drug development division, Calibr-Skaggs Institute for Innovative Medicines, have completed a Phase 1 clinical trial evaluating the safety of the sCAR-T platform (CLBR001) paired with a CD19-targeted switch (SWI019) for B-cell malignancies (NCT04450069). Initial results announced underscore the potential of this therapy. The technology is now being tested in a Phase 1 clinical trial for metastatic breast cancer, with an additional Phase 1 trial for autoimmune diseases launching this year. #WorldCancerDay #CancerResearch #Immunotherapy #BreastCancerResearch #ClinicalTrials

Scripps Research

17,297 просмотров • 7 месяцев назад

Imagine qualifying as a doctor in the UK, only to be told there is no NHS training job for you in your home country. That is the reality facing thousands of UK medical graduates. The taxpayer invests in medical education. Medical graduates complete a five to six year demanding medical degree, graduate with debts often exceeding £100,000, and commit themselves to serving patients in the NHS. Yet in 2025, more than 40,000 applicants applied for just 10,000 specialty training jobs. Some doctors end up unemployed because they cannot find jobs as fully qualified doctors. These training posts are not optional extras. They are the route to becoming the specialist Consultants and GPs our NHS depends on. Without them, doctors cannot progress in their careers and patients ultimately lose future specialists. Yet UK medical graduates are not being prioritised for these NHS training jobs. Prioritising UK medical graduates for speciality training jobs is coherent workforce planning. At the same time, there must be safeguards for international doctors with significant NHS experience who are already contributing to patient care. Right now, the system satisfies no one. It creates unemployment, fuels insecurity, and weakens the future medical workforce. That is not sustainable and it must change.
0:14

Imagine qualifying as a doctor in the UK, only to be told there is no NHS training job for you in your home country. That is the reality facing thousands of UK medical graduates. The taxpayer invests in medical education. Medical graduates complete a five to six year demanding medical degree, graduate with debts often exceeding £100,000, and commit themselves to serving patients in the NHS. Yet in 2025, more than 40,000 applicants applied for just 10,000 specialty training jobs. Some doctors end up unemployed because they cannot find jobs as fully qualified doctors. These training posts are not optional extras. They are the route to becoming the specialist Consultants and GPs our NHS depends on. Without them, doctors cannot progress in their careers and patients ultimately lose future specialists. Yet UK medical graduates are not being prioritised for these NHS training jobs. Prioritising UK medical graduates for speciality training jobs is coherent workforce planning. At the same time, there must be safeguards for international doctors with significant NHS experience who are already contributing to patient care. Right now, the system satisfies no one. It creates unemployment, fuels insecurity, and weakens the future medical workforce. That is not sustainable and it must change.

Dr Haseena Wazir

99,576 просмотров • 7 месяцев назад

Some of the most serious diseases in women progress for a long time without showing any symptoms. Cervical diseases, in particular, are often completely silent in the early stages. They can develop over years without pain, bleeding, or any noticeable complaints. Therefore, a Pap smear is not just a test, but one of the most powerful tools for early diagnosis. A Pap smear is a screening test that takes a sample of cells from the cervix. The aim is to detect cellular changes before they turn into cancer. Because cervical cancer is not a disease that develops suddenly; it is mostly the result of long-term cellular changes. The most critical point is this: Most patients feel nothing in the early stages. So, the approach of "if there are no symptoms, there is no problem" is not valid for this disease. Thanks to Pap smears: Precancerous lesions can be detected early. Treatment becomes much easier and more effective. Disease progression can be largely prevented. ACOG recommendations: 21–29 years → Pap smear every 3 years 30–65 years → * Pap smear every 3 years * or HPV test every 5 years * or co-test every 5 years (smear + HPV test) After 65 years of age, screening is discontinued in suitable patients. The procedure is short, often painless, and does not affect daily life. Common concerns in society are embarrassment, fear, or procrastination. However, a screening that takes only a few minutes can prevent a serious disease that could last for years.
0:10

Some of the most serious diseases in women progress for a long time without showing any symptoms. Cervical diseases, in particular, are often completely silent in the early stages. They can develop over years without pain, bleeding, or any noticeable complaints. Therefore, a Pap smear is not just a test, but one of the most powerful tools for early diagnosis. A Pap smear is a screening test that takes a sample of cells from the cervix. The aim is to detect cellular changes before they turn into cancer. Because cervical cancer is not a disease that develops suddenly; it is mostly the result of long-term cellular changes. The most critical point is this: Most patients feel nothing in the early stages. So, the approach of "if there are no symptoms, there is no problem" is not valid for this disease. Thanks to Pap smears: Precancerous lesions can be detected early. Treatment becomes much easier and more effective. Disease progression can be largely prevented. ACOG recommendations: 21–29 years → Pap smear every 3 years 30–65 years → * Pap smear every 3 years * or HPV test every 5 years * or co-test every 5 years (smear + HPV test) After 65 years of age, screening is discontinued in suitable patients. The procedure is short, often painless, and does not affect daily life. Common concerns in society are embarrassment, fear, or procrastination. However, a screening that takes only a few minutes can prevent a serious disease that could last for years.

Op. Dr. Mehmet Bekir Şen

192,329 просмотров • 5 месяцев назад

🧪 Back in the 1980s and early '90s, researchers started uncovering something suprising inside the aloe vera plant: a sugar molecule called acemannan. It wasn't just soothing burns or helping skin heal faster, it was communicating with the immune system. In lab tests and hospital settings, doctors noticed that aloe's compounds could help white blood cells "wake up" and respond more efficiently without overstimulation. 🦠One doctor working with HIV patients even saw immune markers improve after giving them the pure aloe extract. But as soon as the research gained traction, the story fizzled out. Funding dried up, pharmaceutical interests shifted focus, and the patents for acemannan extraction quietly got tucked away under corporate control. What had started as a promising immune discovery suddenly and conveniently disappeared. 🔒 Today, aloe is marketed mostly for skin care or digestion, but that's only a fraction of what it can do. Beneath its green skin lies a compound so unique that it was once granted "orphan drug status" by the FDA in 1995 for its role in supporting immune recovery in HIV patients. That should've been front page news but instead it was buried under the noise of pharmaceutical progress. 🌱 Interesting how this humble desert plant was quietly doing what billions of research dollars were still trying to replicate (helping the body remember how to heal itself but safely with no side effects, no contraindications and no toxicity levels.... ⭐️ Today only about 130 patents for proper extraction and stabilization exist, the most recent patent having the highest immune modulating 1,100 fractions in the world. This essentially means ideal compatibility for the body to recognize and use acemannan immediately upon taking. ❔ Think about how disruptive this could be if people actually started understanding how incredibly powerful their immune system was when it's function properly... -laurae_ramos
0:11

🧪 Back in the 1980s and early '90s, researchers started uncovering something suprising inside the aloe vera plant: a sugar molecule called acemannan. It wasn't just soothing burns or helping skin heal faster, it was communicating with the immune system. In lab tests and hospital settings, doctors noticed that aloe's compounds could help white blood cells "wake up" and respond more efficiently without overstimulation. 🦠One doctor working with HIV patients even saw immune markers improve after giving them the pure aloe extract. But as soon as the research gained traction, the story fizzled out. Funding dried up, pharmaceutical interests shifted focus, and the patents for acemannan extraction quietly got tucked away under corporate control. What had started as a promising immune discovery suddenly and conveniently disappeared. 🔒 Today, aloe is marketed mostly for skin care or digestion, but that's only a fraction of what it can do. Beneath its green skin lies a compound so unique that it was once granted "orphan drug status" by the FDA in 1995 for its role in supporting immune recovery in HIV patients. That should've been front page news but instead it was buried under the noise of pharmaceutical progress. 🌱 Interesting how this humble desert plant was quietly doing what billions of research dollars were still trying to replicate (helping the body remember how to heal itself but safely with no side effects, no contraindications and no toxicity levels.... ⭐️ Today only about 130 patents for proper extraction and stabilization exist, the most recent patent having the highest immune modulating 1,100 fractions in the world. This essentially means ideal compatibility for the body to recognize and use acemannan immediately upon taking. ❔ Think about how disruptive this could be if people actually started understanding how incredibly powerful their immune system was when it's function properly... -laurae_ramos

𝚃𝙷𝙴 𝚆𝙷𝙸𝚃𝙴 𝚁𝙰𝙱𝙱𝙸𝚃

204,218 просмотров • 5 месяцев назад

My physical therapist opened a superb gym in a beautiful and intimate space in a great location at 32 East 57th Street next to Atria. The concept integrates physical therapy with weight training, cardio, sauna, steam, cold plunge, sensory deprivation, VO2 max and all the other testing you need to determine your base line fitness and monitor your progress thereafter as well as much more. Vosk has the best equipment I have ever seen in any gym and extremely experienced trainers and physical therapists. It is a great place for serious athletes and those interested in longevity or just getting in great shape. While it is a high end gym, the price is fair when you consider the cost of the 96 training and/or physical therapy sessions included in your annual membership. The integration of physical therapy and training yields much better and safer outcomes. I have also found my training consistency is much greater since I prepaid for the sessions. If you want to learn more, go to or email Vitaly who founded Vosk at hello@voskcenter.com. The first 40 members who mention this X post will have their initiation fees waived. Membership is limited to ensure a great experience.
0:18

My physical therapist opened a superb gym in a beautiful and intimate space in a great location at 32 East 57th Street next to Atria. The concept integrates physical therapy with weight training, cardio, sauna, steam, cold plunge, sensory deprivation, VO2 max and all the other testing you need to determine your base line fitness and monitor your progress thereafter as well as much more. Vosk has the best equipment I have ever seen in any gym and extremely experienced trainers and physical therapists. It is a great place for serious athletes and those interested in longevity or just getting in great shape. While it is a high end gym, the price is fair when you consider the cost of the 96 training and/or physical therapy sessions included in your annual membership. The integration of physical therapy and training yields much better and safer outcomes. I have also found my training consistency is much greater since I prepaid for the sessions. If you want to learn more, go to or email Vitaly who founded Vosk at [email protected]. The first 40 members who mention this X post will have their initiation fees waived. Membership is limited to ensure a great experience.

Bill Ackman

926,062 просмотров • 3 месяцев назад

Wes Streeting, "We are beginning to see things move in the right direction" ➡️In 2019, less than 10,000 patients in hospital corridors, last year, it was around 1,000,000 ➡️Labour's updated GP contract does not provide a budget to hire more GPs even though we have a need for more GPs and many unemployed GPs, instead Labour provided budgets to hire non GP staff eg PAs ➡️Last year 40,000 doctors applied for 10,000 training places, because Labour underfunded training places, meaning we have fewer GPs and fewer specialist doctors ➡️ A&E performance remains well below NHS standards: only about 71–73% of patients were seen within 4 hours, far short of the 95% target ➡️ Ambulance response times for urgent cases (e.g., strokes) still miss national targets, and routine waiting lists remain very high ➡️ 6 in 10 said they were dissatisfied, indicating widespread public frustration with current service quality ➡️ Public Accounts Committee found that key waiting‑time improvement targets were not met, that long waits persist (including year‑plus waits) ➡️ A Royal College of Nursing report (January 2026) describes widespread corridor care - patients left in hallways, dining rooms, and even viewing rooms because of overcrowding, a situation that was labelled a “national emergency” ➡️ Several NHS trusts in England (including three in Surrey) recently declared critical incidents due to surges in demand in A&E - showing that emergency services continue to be pushed to breaking point ➡️ Independent survey data show that only about 1 in 5 people are satisfied with how the NHS operates, and majorities feel dissatisfied. This is the lowest satisfaction on record and occurred during the period Labour has been in office
0:12

Wes Streeting, "We are beginning to see things move in the right direction" ➡️In 2019, less than 10,000 patients in hospital corridors, last year, it was around 1,000,000 ➡️Labour's updated GP contract does not provide a budget to hire more GPs even though we have a need for more GPs and many unemployed GPs, instead Labour provided budgets to hire non GP staff eg PAs ➡️Last year 40,000 doctors applied for 10,000 training places, because Labour underfunded training places, meaning we have fewer GPs and fewer specialist doctors ➡️ A&E performance remains well below NHS standards: only about 71–73% of patients were seen within 4 hours, far short of the 95% target ➡️ Ambulance response times for urgent cases (e.g., strokes) still miss national targets, and routine waiting lists remain very high ➡️ 6 in 10 said they were dissatisfied, indicating widespread public frustration with current service quality ➡️ Public Accounts Committee found that key waiting‑time improvement targets were not met, that long waits persist (including year‑plus waits) ➡️ A Royal College of Nursing report (January 2026) describes widespread corridor care - patients left in hallways, dining rooms, and even viewing rooms because of overcrowding, a situation that was labelled a “national emergency” ➡️ Several NHS trusts in England (including three in Surrey) recently declared critical incidents due to surges in demand in A&E - showing that emergency services continue to be pushed to breaking point ➡️ Independent survey data show that only about 1 in 5 people are satisfied with how the NHS operates, and majorities feel dissatisfied. This is the lowest satisfaction on record and occurred during the period Labour has been in office

Farrukh

16,912 просмотров • 8 месяцев назад

Grok Summary of Neuralink’s “Two Years of Telepathy” Update Neuralink’s Telepathy is their pioneering brain-computer interface (BCI) aimed at restoring independence for people with paralysis by translating neural signals into digital commands for controlling devices like computers, phones, and robotic limbs. The article reflects on two years of progress, highlighting clinical trials with 21 participants (Neuralnauts), technical breakthroughs, personal stories of transformation, challenges, and ambitious future goals. • Key Milestones: Enrolled 21 participants worldwide; achieved information transfer rates over 10 bits per second (surpassing able-bodied mouse control); developed a mental ten-finger keyboard for typing up to 40 words per minute; launched the VOICE trial for real-time speech restoration targeting 140 words per minute; expanded trials from three in 2024 to multiple per month in 2025, with no serious device-related adverse events. • Patient Experiences and Impacts: ◦ Noland (first recipient, spinal cord injury): Regained independence for studying, reading, and college (best grades ever); describes it as reclaiming lost life. ◦Nick (paralyzed four years): Controls robotic arm for tasks like feeding; feels natural gestures, restoring a sense of movement. ◦Sebastian (medical student, recent injury): Uses for 17 hours daily to annotate papers and multitask in lectures, boosting productivity. ◦Audrey (20-year injury): Creates abstract art, gains online fame, plans a gallery; feels her mind “a little free.” ◦Jake (ALS): Uses mental keyboard for tasks; sees himself as a “superhero” for his son. ◦Brad (ALS): Controls wheelchair camera to watch his son at events; views ALS as an opportunity for innovation. • Technical Advancements: Translates thoughts into intuitive cursor/robotic control; detects bilateral hand signals from single-sided implants; adapts to individual brain variations during surgery; upcoming upgrades include tripling electrodes to 3000 and exploring less invasive insertion methods. • Challenges: Variations in brain anatomy and disease stages affect performance; early thread retraction issues addressed; communication loss in ALS patients (up to 95% decline ventilation); need for faster, more natural control. • Future Plans: Enhance hardware and procedures for consistency; advance speech restoration; accelerate enrollments; invite quadriplegic individuals (from spinal cord injury, ALS, or stroke) to join the patient registry; seek talent to scale solutions.
0:12

Grok Summary of Neuralink’s “Two Years of Telepathy” Update Neuralink’s Telepathy is their pioneering brain-computer interface (BCI) aimed at restoring independence for people with paralysis by translating neural signals into digital commands for controlling devices like computers, phones, and robotic limbs. The article reflects on two years of progress, highlighting clinical trials with 21 participants (Neuralnauts), technical breakthroughs, personal stories of transformation, challenges, and ambitious future goals. • Key Milestones: Enrolled 21 participants worldwide; achieved information transfer rates over 10 bits per second (surpassing able-bodied mouse control); developed a mental ten-finger keyboard for typing up to 40 words per minute; launched the VOICE trial for real-time speech restoration targeting 140 words per minute; expanded trials from three in 2024 to multiple per month in 2025, with no serious device-related adverse events. • Patient Experiences and Impacts: ◦ Noland (first recipient, spinal cord injury): Regained independence for studying, reading, and college (best grades ever); describes it as reclaiming lost life. ◦Nick (paralyzed four years): Controls robotic arm for tasks like feeding; feels natural gestures, restoring a sense of movement. ◦Sebastian (medical student, recent injury): Uses for 17 hours daily to annotate papers and multitask in lectures, boosting productivity. ◦Audrey (20-year injury): Creates abstract art, gains online fame, plans a gallery; feels her mind “a little free.” ◦Jake (ALS): Uses mental keyboard for tasks; sees himself as a “superhero” for his son. ◦Brad (ALS): Controls wheelchair camera to watch his son at events; views ALS as an opportunity for innovation. • Technical Advancements: Translates thoughts into intuitive cursor/robotic control; detects bilateral hand signals from single-sided implants; adapts to individual brain variations during surgery; upcoming upgrades include tripling electrodes to 3000 and exploring less invasive insertion methods. • Challenges: Variations in brain anatomy and disease stages affect performance; early thread retraction issues addressed; communication loss in ALS patients (up to 95% decline ventilation); need for faster, more natural control. • Future Plans: Enhance hardware and procedures for consistency; advance speech restoration; accelerate enrollments; invite quadriplegic individuals (from spinal cord injury, ALS, or stroke) to join the patient registry; seek talent to scale solutions.

DogeDesigner

17,651 просмотров • 7 месяцев назад

The White House just put a 100% tariff on foreign drones. The message: stop buying from China, start building at home. Powerus has been building at home the whole time, and its supply chain reflects it: a $30M strategic investment from $UMAC (as of this post, trading up 28%!), on top of an existing relationship supplying U.S.-made drone components. Kinetic counter-drone interceptors. Heavy-lift cargo drones. Tactical FPV platforms. Autonomous maritime systems. Manufactured out of Charlotte, North Carolina. The U.S. Air Force is already betting on it too: an IDIQ worth up to $90 million for the Guardian-2 interceptor. A defense prime followed with an order for 1,500 U.S.-made FPV aircraft. Powerus has proposed a merger with Aureus Greenway Holdings (Nasdaq: PUSA), targeted to close in Q4 2026 following SEC effectiveness of the Form S-4 on August 12th. The transaction remains subject to closing conditions, and there is no assurance it will be completed. Learn more: Disclaimer: This content was produced in collaboration with the client and is intended for informational purposes only. It does not constitute financial or investment advice. Always conduct your own research before making any financial decisions.
0:16

The White House just put a 100% tariff on foreign drones. The message: stop buying from China, start building at home. Powerus has been building at home the whole time, and its supply chain reflects it: a $30M strategic investment from $UMAC (as of this post, trading up 28%!), on top of an existing relationship supplying U.S.-made drone components. Kinetic counter-drone interceptors. Heavy-lift cargo drones. Tactical FPV platforms. Autonomous maritime systems. Manufactured out of Charlotte, North Carolina. The U.S. Air Force is already betting on it too: an IDIQ worth up to $90 million for the Guardian-2 interceptor. A defense prime followed with an order for 1,500 U.S.-made FPV aircraft. Powerus has proposed a merger with Aureus Greenway Holdings (Nasdaq: PUSA), targeted to close in Q4 2026 following SEC effectiveness of the Form S-4 on August 12th. The transaction remains subject to closing conditions, and there is no assurance it will be completed. Learn more: Disclaimer: This content was produced in collaboration with the client and is intended for informational purposes only. It does not constitute financial or investment advice. Always conduct your own research before making any financial decisions.

Mario Nawfal

112,297 просмотров • 1 месяц назад